Skip to main content
AVAI
OTC Technology

Avai Bio 10-Q: Going Concern Doubt, $4.35M Working Capital Deficit, $10M Raise Needed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.075
Mkt Cap
$11.544M
52W Low
$0.07
52W High
$0.8
52W Position info
7.1% above low
Off High info
91% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

AVAI is trading near its 52-week low of $0.07 (7.1% above the low) on light trading volume (0.1× avg).

Summary

Avai Bio's September-quarter 10-Q shows no revenue, $121,948 of cash, a $4.35M working capital deficit and renewed going-concern doubt, with management saying it needs roughly $10M of new capital.


Key Events · Earnings and Guidance · AVAI

  • Going Concern Doubt Reaffirmed

    Citing recurring losses, the company reports 'substantial doubt about the Company's ability to continue as a going concern,' dependent on raising additional investment capital.

  • Cash Burn Outpaces Thin Cash Balance

    Net cash used in operating activities was $489,577 for the six months ended September 30, 2026, against a cash balance of just $121,948.

  • Working Capital Deficit Widens

    Working capital deficit grew to $4,346,839 from $3,298,511 at March 31, 2026, and stockholders' deficit widened to $3,415,806 from $2,815,155.

  • Company Says It Needs ~$10M

    Management states that to fully implement its business plan 'we will need to raise about $10,000,000,' which would mean further equity or convertible debt issuance.


Analysis · AVAI · Technology

The funding gap is the whole story for this $0.075 OTC stock. Avai Bio still has no revenue and burned $489,577 of cash on operations in the six months to September 30, 2026, leaving $121,948 of cash against a working capital deficit of $4,346,839. Management repeats that there is substantial doubt about the company's ability to continue as a going concern and says it needs to raise about $10,000,000 to fully implement its business plan — money that would almost certainly come from more share issuance, on top of the 154.4M shares already outstanding. The loss narrowed to $805,281 from $940,605 on lower marketing and G&A spend, but the balance sheet got weaker, not stronger: stockholders' deficit widened to $3,415,806 and management concluded its disclosure controls and procedures were not effective.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVAI was trading at $0.08 on OTC in the Technology sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $0.07 to $0.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVAI - Latest Insights

AVAI
Sep 30, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.12586
Real-time Price: $0.075 info
Change: -$0.05086 (-40%) info
Market Cap: $11.544M info
AVAI
Aug 13, 2026, 7:18 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.120
Real-time Price: $0.075 info
Change: -$0.045 (-38%) info
Market Cap: $11.544M info
AVAI
Jul 14, 2026, 3:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.1681
Real-time Price: $0.075 info
Change: -$0.0931 (-55%) info
Market Cap: $11.544M info
AVAI
May 08, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.300
Real-time Price: $0.075 info
Change: -$0.225 (-75%) info
Market Cap: $11.544M info
AVAI
Feb 12, 2026, 4:20 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.4021
Real-time Price: $0.075 info
Change: -$0.3271 (-81%) info
Market Cap: $11.544M info